Analysis of hepatitis C NS5A resistance associated polymorphisms using ultra deep single molecule real time (SMRT) sequencing

Antiviral Research

Volumn 126, Issue , 2016, Pages 81-89

  Bergfors, Assar ^a   Leenheer, Daniël ^a,b   Bergqvist, Anders ^a   Ameur, Adam ^a   Lennerstrand, Johan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Deep sequencing; Hepatitis C virus; NS5A; Pacific biosciences; RAV; Resistance

Indexed keywords

ANTIVIRUS AGENT; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ANTIVIRAL RESISTANCE; DNA SEQUENCE; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; HEPACIVIRUS; HEPATITIS C; HIGH THROUGHPUT SEQUENCING; HUMAN; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROCEDURES; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BASE SEQUENCE; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84952789537     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.12.005     Document Type: Article

References (44)

1. Burrows-Wheeler Aligner [WWW Document], n.d. URL http://bio-bwa.sourceforge.net/ (accessed 21.5.14.).
2. LCI-richtlijn Hepatitis C [WWW Document], n.d. URL http://www.rivm.nl/Documenten-en-publicaties/Professioneel-Praktisch/Richtlijnen/Infectieziekten/LCI-richtlijnen/LCI-richtlijn-Hepatitis-C (accessed 27.2.14.).
3. SAMtools [WWW Document], n.d. URL http://samtools.sourceforge.net/ (accessed 21.5.14.).
4. WHO | Hepatitis C [WWW Document], n.d. WHO. URL http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed 27.1.14.).
5. Accuscript RT Products, n.d. AccuScript High Fidelity Reverse Transcriptase Products. Available at: http://www.chem.agilent.com/library/datasheets/public/tb108-71067.pdf.
6. J.S. Au, and P.J. Pockros Novel Therapeutic Approaches for hepatitis C Clin. Pharmacol. Ther. 95 2014 78 88 10.1038/clpt.2013.206
7. Babraham Bioinformatics - FastQC A Quality Control tool for High Throughput Sequence Data [WWW Document], n.d. URL http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ (accessed 5.21.14.).
8. M.O. Carneiro, C. Russ, M. Ross, P. Cahill, S. Gabriel, C. Nusbaum, and M.A. DePristo Evaluating the Potential of New Sequencing Technologies for Genotyping and Variation Discovery in Human Data 2012 Broad Institute of MIT and Harvard http://www.pacb.com/wp-content/uploads/2015/09/Poster-Genotyping-and-Variation-Discovery-in-Human-Data2.pdf
9. M.O. Carneiro, C. Russ, M.G. Ross, S.B. Gabriel, C. Nusbaum, and M.A. DePristo Pacific biosciences sequencing technology for genotyping and variation discovery in human data BMC Genom. 13 2012 375 10.1186/1471-2164-13-375
10. L. Cavelier, A. Ameur, S. Häggqvist, I. Höijer, N. Cahill, U. Olsson-Strömberg, and M. Hermanson Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing BMC Cancer 15 2015 45 10.1186/s12885-015-1046-y
11. J. Cline, J.C. Braman, and H.H. Hogrefe PCR fidelity of pfu DNA polymerase and other thermostable DNA polymerases Nucleic Acids Res. 24 1996 3546 3551
12. D.A. DeGoey, J.T. Randolph, D. Liu, J. Pratt, C. Hutchins, P. Donner, A.C. Krueger, M. Matulenko, S. Patel, C.E. Motter, L. Nelson, R. Keddy, M. Tufano, D.D. Caspi, P. Krishnan, N. Mistry, G. Koev, T.J. Reisch, R. Mondal, T. Pilot-Matias, Y. Gao, D.W.A. Beno, C.J. Maring, A. Molla, E. Dumas, A. Campbell, L. Williams, C. Collins, R. Wagner, and W.M. Kati Discovery of ABT-267, a Pan-genotypic inhibitor of HCV NS5A J. Med. Chem. 57 2014 2047 2057 10.1021/jm401398x
13. J. Dietz, S. Susser, C. Berkowski, D. Perner, S. Zeuzem, and C. Sarrazin Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients PloS One 10 2015 e0134395 10.1371/journal.pone.0134395
14. H. Dvory-Sobol, B. Doehle, E. Svarovskaia, J. McCarville, P. Pang, N. Afdhal, K. Kowdley, J. McHutchison, M. Miller, and H. Mo The prevalence of HCV NS5A, nucleoside and protease inhibitor resistance associated variants and the effects on treatment with ledipasvir sofosbuvir ± RBV in the Phase 3 ION studies Antivir. Ther. 19 Suppl. 1 2014 A38 Available at: http://www.natap.org/2014/ResisWksp/ResisWksp-07.htm
15. N.S. Eyre, G.N. Fiches, A.L. Aloia, K.J. Helbig, E.M. McCartney, C.S.P. McErlean, K. Li, A. Aggarwal, S.G. Turville, and M.R. Beard Dynamic imaging of the hepatitis C virus NS5A protein during a productive infection J. Virol. 2014 10.1128/JVI.02490-13 JVI.02490-13
16. P. Ferenci, D. Bernstein, J. Lalezari, D. Cohen, Y. Luo, C. Cooper, E. Tam, R.T. Marinho, N. Tsai, A. Nyberg, T.D. Box, Z. Younes, P. Enayati, S. Green, Y. Baruch, B.R. Bhandari, F.A. Caruntu, T. Sepe, V. Chulanov, E. Janczewska, G. Rizzardini, J. Gervain, R. Planas, C. Moreno, T. Hassanein, W. Xie, M. King, T. Podsadecki, and K.R. Reddy ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV N. Engl. J. Med. 370 2014 1983 1992 10.1056/NEJMoa1402338
17. I.J. Fijalkowska, R.M. Schaaper, and P. Jonczyk DNA replication fidelity in Escherichia coli: a multi-DNA polymerase affair FEMS Microbiol. Rev. 36 2012 1105 1121 10.1111/j.1574-6976.2012.00338.x
18. R.A. Fridell, D. Qiu, C. Wang, L. Valera, and M. Gao Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system Antimicrob. Agents Chemother. 54 2010 3641 3650 10.1128/AAC.00556-10
19. R.A. Fridell, C. Wang, J.-H. Sun, D.R. O'Boyle, P. Nower, L. Valera, D. Qiu, S. Roberts, X. Huang, B. Kienzle, M. Bifano, R.E. Nettles, and M. Gao Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations Hepatol. Balt. Md 54 2011 1924 1935 10.1002/hep.24594
20. M. Gao, R.E. Nettles, M. Belema, L.B. Snyder, V.N. Nguyen, R.A. Fridell, M.H. Serrano-Wu, D.R. Langley, J.-H. Sun, D.R. O'Boyle, J.A. Lemm, C. Wang, J.O. Knipe, C. Chien, R.J. Colonno, D.M. Grasela, N.A. Meanwell, and L.G. Hamann Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100 10.1038/nature08960
21. L. Goobar-Larsson, L. Wiklund, and S. Schwartz Intracellular hepatitis C virus RNA-dependent RNA polymerase activity Arch. Virol. 146 2001 1553 1570
22. D. Hernandez, N. Zhou, J. Ueland, A. Monikowski, and F. McPhee Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol. 57 2013 13 18 10.1016/j.jcv.2012.12.020
23. M. Houghton The long and winding road leading to the identification of the hepatitis C virus J. Hepatol. 51 2009 939 948 10.1016/j.jhep.2009.08.004
24. J. Keys, S. Zhou, J.A. Anderson, J. Eron, L.A. Rackoff, C. Jabara, and R. Swanstrom Primer ID Informs next-generation sequencing Platforms and Reveals pre-existing drug resistance mutations in the HIV-1 reverse transcriptase coding domain AIDS Res. Hum. Retroviruses 2015 10.1089/AID.2014.0031
25. K.V. Kowdley, S.C. Gordon, K.R. Reddy, L. Rossaro, D.E. Bernstein, E. Lawitz, M.L. Shiffman, E. Schiff, R. Ghalib, M. Ryan, V. Rustgi, M. Chojkier, R. Herring, A.M. Di Bisceglie, P.J. Pockros, G.M. Subramanian, D. An, E. Svarovskaia, R.H. Hyland, P.S. Pang, W.T. Symonds, J.G. McHutchison, A.J. Muir, D. Pound, and M.W. Fried Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis N. Engl. J. Med. 370 2014 1879 1888 10.1056/NEJMoa1402355
26. P. Krishnan, R. Tripathi, M. Irvin, J. Beyer, T. Reisch, G. Schnell, W. Xie, X. Zhou, L. Larsen, J. Kofron, D. Cohen, T. Podsadecki, T. Pilot-Matias, and C. Collins Lack of impact of baseline resistance-associated variants (RAVs) on treatment outcome in the aviator study with ABT-450/r, ABT-333 and ABT-267, +/- ribavirin J. Hepatol. 2014 10.1016/S0168-8278(14)61390-8 S498
27. P. Krishnan, J. Beyer, N. Mistry, G. Koev, T. Reisch, D. DeGoey, W. Kati, A. Campbell, L. Williams, W. Xie, C. Setze, A. Molla, C. Collins, and T. Pilot-Matias In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A Antimicrob. Agents Chemother. 59 2015 979 987 10.1128/AAC.04226-14
28. E.J. Lawitz, D. Gruener, J.M. Hill, T. Marbury, L. Moorehead, A. Mathias, G. Cheng, J.O. Link, K.A. Wong, H. Mo, J.G. McHutchison, and D.M. Brainard A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C J. Hepatol. 57 2012 24 31 10.1016/j.jhep.2011.12.029
29. E. Lawitz, S. Flamm, J.C. Yang, P.S. Pang, Y. Zhu, E. Svarovskaia, J.G. McHutchison, D.L. Wyles, and P.J. Pockros Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks J. Hepatol. 2015
30. I. Lindström, M. Kjellin, N. Palanisamy, K. Bondeson, L. Wesslén, A. Lannergard, and J. Lennerstrand Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden Infect. Dis. Lond. Engl. 1-8 2015 10.3109/23744235.2015.1028097
31. E. Lontok, P. Harrington, A. Howe, T. Kieffer, J. Lennerstrand, O. Lenz, F. McPhee, H. Mo, N. Parkin, T. Pilot-Matias, and V. Miller Hepatitis C virus drug resistance-associated substitutions: state of the art summary Hepatol. Balt. Md 2015 10.1002/hep.27934
32. K.S. Lundberg, D.D. Shoemaker, M.W. Adams, J.M. Short, J.A. Sorge, and E.J. Mathur High-fidelity amplification using a thermostable DNA polymerase isolated from Pyrococcus furiosus Gene 108 1991 1 6
33. T. Nakano, G.M.G. Lau, G.M.L. Lau, M. Sugiyama, and M. Mizokami An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region Liver Int. 32 2012 339 345 10.1111/j.1478-3231.2011.02684.x
34. D.R. Nelson, J.N. Cooper, J.P. Lalezari, E. Lawitz, P.J. Pockros, N. Gitlin, B.F. Freilich, Z.H. Younes, W. Harlan, R. Ghalib, G. Oguchi, P.J. Thuluvath, G. Ortiz-Lasanta, M. Rabinovitz, D. Bernstein, M. Bennett, T. Hawkins, N. Ravendhran, A.M. Sheikh, P. Varunok, K.V. Kowdley, D. Hennicken, F. McPhee, K. Rana, E.A. Hughes ALLY-3 Study Team All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study Hepatol. Balt. Md 2015 10.1002/hep.27726
35. N. Palanisamy, A. Danielsson, C. Kokkula, H. Yin, K. Bondeson, L. Wesslén, A.-S. Duberg, and J. Lennerstrand Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a Antivir. Res. 99 2013 12 17 10.1016/j.antiviral.2013.04.018
36. S. Paolucci, L. Fiorina, B. Mariani, R. Gulminetti, S. Novati, G. Barbarini, R. Bruno, and F. Baldanti Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients Virol. J. 10 2013 355 10.1186/1743-422X-10-355
37. E. Pienaar, M. Theron, M. Nelson, and H. Viljoen A quantitative model of error accumulation during PCR amplification Comput. Biol. Chem. 30 2006 102 111 10.1016/j.compbiolchem.2005.11.002
38. E. Poveda, D.L. Wyles, A. Mena, J.D. Pedreira, A. Castro-Iglesias, and E. Cachay Update on hepatitis C virus resistance to direct-acting antiviral agents Antivir. Res. 108 2014 181 191 10.1016/j.antiviral.2014.05.015
39. M.H. Powdrill, E.P. Tchesnokov, R.A. Kozak, R.S. Russell, R. Martin, E.S. Svarovskaia, H. Mo, R.D. Kouyos, and M. Götte Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance Proc. Natl. Acad. Sci. U. S. A. 108 2011 20509 20513 10.1073/pnas.1105797108
40. C. Sarrazin, H. Dvory-Sobol, E.S. Svarovskaia, B. Doehle, R. Martin, S. Zeuzem, E. Lawitz, R. Hyland, P.S. Pang, S. Knox, E. Gane, K. Reddy, N. Afdhal, M. Mizokami, M. Omata, M.D. Miller, H. Mo, and M. Bourlière The prevalence and effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir ± RBV J. Hepatol. 2015
41. M.S. Sulkowski, D.F. Gardiner, M. Rodriguez-Torres, K.R. Reddy, T. Hassanein, I. Jacobson, E. Lawitz, A.S. Lok, F. Hinestrosa, P.J. Thuluvath, H. Schwartz, D.R. Nelson, G.T. Everson, T. Eley, M. Wind-Rotolo, S.-P. Huang, M. Gao, D. Hernandez, F. McPhee, D. Sherman, R. Hindes, W. Symonds, C. Pasquinelli, and D.M. Grasela Daclatasvir plus sofosbuvir for previously treated or Untreated chronic HCV infection N. Engl. J. Med. 370 2014 211 221 10.1056/NEJMoa1306218
42. H. Thorvaldsdóttir, J.T. Robinson, and J.P. Mesirov Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration Brief. Bioinform. 14 2013 178 192 10.1093/bib/bbs017
43. C. Wang, H. Huang, L. Valera, J.-H. Sun, D.R. O'Boyle 2nd, P.T. Nower, L. Jia, D. Qiu, X. Huang, A. Altaf, M. Gao, and R.A. Fridell Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052 Antimicrob. Agents Chemother. 56 2012 1350 1358 10.1128/AAC.05977-11
44. L. Williams, C. Collins, and T. Pilot-Matias Antiviral activity and resistance profiles for ABT-267, a novel HCV NS5A inhibitor, in vitro and during 3-day monotherapy in HCV genotype-1 (GT1)-infected treatment-naïve subjects Abstract 1881 presented at the 63rd annual meeting of the AASLD, Boston, United States 2012